IMMU-114

N/A

Report date: 2023/05/05 17:37:05

Base Information

Drug NameIMMU-114
Drug Alias NameIMMU-114hL243
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHLA-DR antigens-associated invariant chain modulators
TargetsHLA-DR antigens-associated invariant chain
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[5] 

Other Information

ATC CodeN/A
Related LinksN/A